The financials
Teva Pharmaceutical Industries Limited by the numbers
Teva Pharmaceutical Industries Limited (TEVA) reported revenue of $3.98B in Q1 2026 (quarter ended March 31, 2026), up 2.3% from the same quarter a year earlier. That came with a gross margin of 50% and net income of $369M (9.3% of revenue). For the full year FY2025, revenue was $17.3B (+4.3% year on year) and net income $1.41B. Its largest product in 2026-Q2 was Austedo at $676M, 38% of the disclosed total, just ahead of Generics Medicians Including Otc And Biosimilars at 37%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $3.98B | $3.89B | +2.3% |
| Gross profit | $1.97B | $1.88B | +5.1% |
| Operating income | $652M | $519M | +26% |
| Net income | $369M | $214M | +72% |
| Diluted EPS | $0.31 | $0.18 | +72% |
| Product | Revenue | Share |
|---|---|---|
| Austedo | $676M | 38% |
| Generics Medicians Including Otc And Biosimilars | $660M | 37% |
| Ajovy | $116M | 6.5% |
| Other Products | $84M | 4.7% |
| Uzedy | $77M | 4.3% |
| COPAXONE | $61M | 3.4% |
| Respiratory Product | $58M | 3.3% |
| Bendeka And Treanda | $28M | 1.6% |
| License | $17M | 1.0% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $1.76B (+7.7%)
Ajovy grew +84% year on yearProduct And Service Other -1050% year on year
Segment Latestquarter on quarteryear on year
- Austedo$676.0M$676.0MQoQ +21%year on year +37%+21%+37%
- Generics Medicians Including Otc And Biosimilars$660.0M$660.0MQoQ +7.8%year on year -31%+7.8%-31%
- Ajovy$116.0M$116.0MQoQ +33%year on year +84%+33%+84%
- Other Products$84.0M$84.0MQoQ -32%year on year -24%-32%-24%
- Uzedy$77.0M$77.0MQoQ +22%year on year +43%+22%+43%
- COPAXONE$61.0M$61.0MQoQ -1.6%year on year -1.6%-1.6%-1.6%
- Respiratory Product$58.0M$58.0MQoQ -1.7%year on year +5.5%-1.7%+5.5%
- Bendeka And Treanda$28.0M$28.0MQoQ +3.7%year on year -30%+3.7%-30%
- License$17.0M$17.0MQoQ -19%year on year -41%-19%-41%
- Anda--QoQ -year on year ---
- Distribution Service$0.00$0.00QoQ -year on year ---
- Product And Service Other−$19.0M−$19.0MQoQ -195%year on year -1050%-195%-1050%
Drug Manufacturers - Specialty & Generic
Ranks #15 of 28 by Smart Score